ChiCTR2600127089 版本V1.0 版本创建时间2026/06/24 14:31:59 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600127089 

最近更新日期:

Date of Last Refreshed on:

2026-06-24 14:31:23 

注册时间:

Date of Registration:

2026-06-24 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

儿童肠造瘘术后关瘘失败的原因分析及临床诊治研究

Public title:

Analysis of Causes and Clinical Management of Failed Closure Following Pediatric Enterostomy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

儿童肠造瘘术后关瘘失败的原因分析及临床诊治研究

Scientific title:

Analysis of Causes and Clinical Management of Failed Closure Following Pediatric Enterostomy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

田礼 

研究负责人:

余东海 

Applicant:

Tian Li 

Study leader:

Yu Donghai 

申请注册联系人电话:

Applicant telephone:

+86 13237132565

研究负责人电话:

Study leader's
telephone:

+86 27 63639759

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

tianli0080@163.com

研究负责人电子邮件:

Study leader's E-mail:

yudonghaitj@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖北省武汉市解放大道1095号

研究负责人通讯地址:

湖北省武汉市解放大道1095号

Applicant address:

No. 1095 Jiefang Avenue, Wuhan City, Hubei Province

Study leader's address:

1095# Jiefang Avenue, Qiaokou District, Wuhan, Hubei,China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

华中科技大学同济医学院附属同济医院

Applicant's institution:

Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

研究负责人所在单位:

华中科技大学同济医学院附属同济医院

Affiliation of the Leader:

Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

TJ-IRB202604053

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

华中科技大学同济医学院附属同济医院医学伦理委员会

Name of the ethic committee:

Institutional Review Board of Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology

伦理委员会批准日期:

Date of approved by ethic committee:

2026-04-14 00:00:00

伦理委员会联系人:

周璞

Contact Name of the ethic committee:

Zhou Pu

伦理委员会联系地址:

湖北省武汉市解放大道1095号

Contact Address of the ethic committee:

1095# Jiefang Avenue, Qiaokou District, Wuhan, Hubei,China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 27 83662437

伦理委员会联系人邮箱:

Contact email of the ethic committee:

zhoupu_tjh@163.com

研究实施负责(组长)单位:

华中科技大学同济医学院附属同济医院

Primary sponsor:

Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology

研究实施负责(组长)单位地址:

湖北省武汉市解放大道1095号

Primary sponsor's address:

1095# Jiefang Avenue, Qiaokou District, Wuhan, Hubei,China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖北省

市(区县):

Country:

China

Province:

Hubei

City:

单位(医院):

华中科技大学同济医学院附属同济医院

具体地址:

湖北省武汉市解放大道1095号

Institution
hospital:

Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology

Address:

1095# Jiefang Avenue, Qiaokou District, Wuhan, Hubei,China

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Independent Research Topic

研究疾病:

先天性巨结肠,巨结肠类缘病  

Target disease:

Hirschsprung Disease;Intestinal neuronal dysplasia

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

本研究旨在分析多次肠造口闭合失败儿童的管理策略与结局。  

Objectives of Study:

This study aimed to analyze the management strategies and clinical outcomes for this complex patient population.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄<14 周岁的儿童; 2.因先天性或获得性胃肠道疾病行肠造口术(回肠造口或结肠造口),且既往至少经历过1 次造口闭合术失败; 3.造口闭合术失败的定义:既往造口闭合术后,出现明确的与手术失败相关的特异性症状,具体包括:持续性或进行性加重的腹胀;反复呕吐(呕吐物含胆汁或粪汁);反复肠炎发作;顽固性便秘(定义为经保守治疗无效,每周排便≤2 次)。

Inclusion criteria

1. Children younger than 14 years; 2.History of enterostomy (ileostomy or colostomy) for congenital or acquired gastrointestinal disease, followed by at least one prior unsuccessful attempt at closure; 3. Definition of Closure Failure: Documented onset of definitive symptoms related to surgical failure after the previous closure procedure, specifically including: persistent or progressively worsening abdominal distension;recurrent vomiting (bilious or feculent emesis);recurrent enteritis;refractory constipation (defined as <=2 bowel movements per week unresponsive to conservative management).

排除标准:

1.因肠道恶性肿瘤、活动性感染性肠炎(如肠结核)或炎症性肠病(如克罗恩病),首次行肠造口术及造口闭合术的患者; 2.法定监护人拒绝本次确定性手术,或拒绝参与本研究及术后随访的患者; 3.临床病历资料不完整,无法明确判断造口闭合术失败原因或评估预后的患者; 4.合并严重先天性或终末期心、肝、肾、神经系统疾病,无法耐受再次手术及麻醉的患者; 5.首次造口闭合术后,因外伤、医源性损伤等外界因素需再次手术的患者。

Exclusion criteria:

1. Patients whose initial enterostomy and closure were performed for intestinal malignancy, active infectious enteritis (e.g., tuberculosis), or inflammatory bowel disease (e.g., Crohn's disease); 2. Patients whose legal guardians declined the current definitive surgery or refused to participate in the study and follow-up; 3.Patients with incomplete clinical records that precluded definitive determination of the cause of closure failure or assessment of outcomes; 4. Patients with severe congenital or end-stage disease of the heart, liver, kidneys, or nervous system, rendering them unfit for reoperation or anesthesia; 5. Patients who required reoperation due to external factors such as trauma or iatrogenic injury following the initial closure attempt.

研究实施时间:

Study execute time:

From 2026-01-18 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-07-01 00:00:00 To 2026-10-31 00:00:00

干预措施:

Interventions:

组别:

观察组

样本量:

60

Group:

Observation group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖北省 

市(区县):

 

Country:

China

Province:

Hubei

City:

单位(医院):

华中科技大学同济医学院附属同济医院 

单位级别:

三级甲等 

Institution
hospital:

Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

人口统计学特征

指标类型:

主要指标

Outcome:

Demographic characteristics

Type:

Primary indicator

测量时间点:

术后1年

测量方法:

随访

Measure time point of outcome:

One year after surgery

Measure method:

Follow-up

指标中文名:

术后病理结果

指标类型:

主要指标

Outcome:

Postoperative pathological results

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠道功能预后

指标类型:

主要指标

Outcome:

Prognosis of intestinal function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age 14 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Do not share.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF采集

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-06-24 14:31:23